Eisai will now take ownership of the Japanese rights to differentiated anti-PD-1 therapy, Hetronifly.

Cancer immunotherapy has been a game-changer, but many tumors still find ways to slip past the immune system. New research ...

A novel neoadjuvant therapy combining PD-1 blockade and chemoradiotherapy shows promising results in treating advanced rectal ...

Golidocitinib combined with PD-1 antibodies achieved a 44.3% response rate in NSCLC patients post anti-PD-1 therapy progression. The combination therapy showed a complete response rate of 23.9% and a ...

PD-1 and PD-L1 inhibitors are types of immune checkpoint inhibitors, which are immunotherapy medications for treating cancer. Immunotherapy helps the immune system find and kill cancer cells. Some ...

A phase II study of anlotinib plus penpulimab as first-line treatment for persistent, recurrent, or metastatic cervical cancer: Results from ALTER-GO-020 trial. This is an ASCO Meeting Abstract from ...

We're going to get started. Thank you, everyone, for joining us here in Berlin, and there are many more of you that are online. Welcome to the solid tumor update that we're having at ESMO 2025. We're ...

The market opportunities in the PD-1 Resistant Head and Neck Cancer sector include the rising need for salvage therapies due to resistance to standard treatments, the proliferation of next-gen ...

In terms of safety, among participants receiving monotherapy and combination therapy, 19 (27.9%) and 26 (35.6%) reported treatment-related adverse events (TRAEs) of Grade 3 or higher, respectively.